Disclaimer: This information is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Clinical decisions must always be made by a qualified healthcare professional in light of the patient's individual circumstances and the most current evidence-based guidelines.

Active Management Of Third Stage Of Labor

Overview

• Definition: Active Management of Third Stage of Labor (AMTSL) refers to a package of interventions performed immediately after the birth of the baby to facilitate the delivery of the placenta and prevent postpartum hemorrhage (PPH), the leading direct cause of maternal mortality globally.
• Epidemiology: Postpartum hemorrhage (PPH), defined as blood loss of ≥500 mL after vaginal birth or ≥1000 mL after cesarean section, affects approximately 1-5% of all births. It accounts for about 25% of maternal deaths worldwide. AMTSL, particularly the administration of a prophylactic uterotonic, is highly effective in reducing the incidence of PPH by 60-70% and the need for blood transfusion by up to 50%.
• Classification: Historically, AMTSL encompassed three key components:
  1. Administration of a prophylactic uterotonic.
  2. Controlled Cord Traction (CCT).
  3. Uterine massage after placental delivery. Current World Health Organization (WHO) guidelines emphasize the prophylactic uterotonic as the critical and essential component, while the routine inclusion of CCT and uterine massage for prevention in low-risk women is now less emphasized for universal application, though still performed in many settings.

Pathophysiology

• Mechanism: The primary mechanism of PPH is uterine atony (failure of the uterus to contract effectively after birth). AMTSL directly addresses this:
  • Uterotonic administration: Stimulates strong, sustained uterine contractions. These contractions cause physiological myometrial retraction, which compresses the blood vessels at the placental implantation site (where the placenta has detached), effectively acting as living ligatures and preventing excessive bleeding.
  • Controlled Cord Traction (CCT): Applied once signs of placental separation are present, CCT aims to expedite placental delivery, reducing the time the uterus is exposed to the potential for atony and minimizing blood loss during the third stage.
  • Uterine massage: Historically thought to stimulate contractions and expel clots, its routine role for prevention is debated, but palpation of the uterus to assess tone and intervene if atony develops is crucial.
• Risk Factors (for PPH, which AMTSL aims to prevent):
  • Uterine Atony (most common cause): Uterine overdistension (e.g., multiple gestation, polyhydramnios, macrosomia), prolonged labor, rapid labor, grand multiparity (≥5 births), chorioamnionitis, use of oxytocin for labor induction/augmentation, general anesthesia, magnesium sulfate administration.
  • Trauma: Lacerations of the cervix, vagina, or perineum; uterine rupture.
  • Tissue: Retained placental tissue (e.g., placenta accreta spectrum, retained succenturiate lobe, retained placental fragments).
  • Thrombin: Coagulopathy (e.g., pre-existing clotting disorders, DIC, severe pre-eclampsia).
• Protective Factors: AMTSL is the most significant protective factor against PPH. Other factors include good nutritional status, antenatal care, and skilled birth attendance.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: AMTSL itself does not have "signs and symptoms" as it is a prophylactic intervention. The "clinical presentation" here refers to the assessment of the third stage of labor, which AMTSL aims to manage effectively to prevent complications.
  • Signs of Placental Separation (after birth of baby): These signs indicate the placenta is ready for delivery:
    • Gush of blood: A sudden trickle or gush of blood from the vagina, often dark red.
    • Lengthening of the umbilical cord: The cord appears to protrude further from the vagina.
    • Globular and firm uterus: The uterus changes from discoid to globular shape and becomes firm.
    • Uterus rises in the abdomen: The uterus rises higher in the abdomen as the separated placenta descends into the lower uterine segment or vagina.
• Early Signs (of potential PPH if AMTSL is ineffective or not performed):
  • Excessive vaginal bleeding (active bleeding beyond expected lochia).
  • Boggy (soft) and enlarged uterus.
  • Unstable vital signs (tachycardia, hypotension, tachypnea) – these are late signs of significant blood loss.

Physical Examination

• Inspection:
  • Assess for active vaginal bleeding (amount, color, presence of clots).
  • Observe the umbilical cord for lengthening.
• Palpation:
  • Immediately after birth, palpate the fundus of the uterus to assess its height and tone. It should be firm and well-contracted.
  • Assess for a "globular" or "boggy" uterus, indicating atony.
  • Perform suprapubic palpation during Controlled Cord Traction to provide counter-pressure and prevent uterine inversion.
• Special Tests: Not applicable for AMTSL directly.

Diagnostic Approach

History Taking

• Key Questions: While AMTSL is standard for all births, certain historical factors increase PPH risk, prompting extra vigilance:
  • Previous PPH?
  • History of uterine surgery (e.g., myomectomy, prior C-section multiple times)?
  • Known bleeding disorders or anticoagulant use?
  • Multigravida status (especially grand multiparity)?
  • Multiple gestation? Polyhydramnios? Suspected macrosomia?
  • Prolonged or augmented labor?
  • Known placenta previa or suspected placenta accreta spectrum?
• Red Flags:
  • Any history increasing PPH risk (as above).
  • Abnormal vital signs (during third stage or immediately postpartum).
  • Excessive bleeding visualized.

Laboratory Tests

• First-Line:
  • Routine prenatal labs: Blood type and screen (for potential transfusion), Hemoglobin/Hematocrit (baseline).
• Confirmatory: Not applicable for AMTSL. If PPH occurs, then:
  • Complete Blood Count (CBC): To assess blood loss and need for transfusion.
  • Coagulation panel (PT/INR, aPTT, Fibrinogen): To identify coagulopathy.
• Monitoring: Repeat CBC post-PPH for recovery assessment.

Imaging

• Recommended: Not applicable for AMTSL.
• Advanced: In cases of suspected retained placental fragments or placenta accreta spectrum, ultrasound may be used after the third stage is completed or complicated.

Management

Acute Management

AMTSL should be initiated immediately following the birth of the baby, ideally within 1 minute of birth.

• Immediate:
  1. Uterotonic Administration: Administer a uterotonic agent to all women.
     • Oxytocin (First-line):
       • Dose: 10 IU (International Units) intramuscularly (IM) or 10 IU intravenously (IV) administered slowly over 1 minute (e.g., diluted in 10 mL saline, given as a bolus). IV bolus should be used with caution due to risk of hypotension and arrhythmias, especially in women with cardiovascular disease. IM is generally preferred due to safety and equivalent efficacy.
       • Timing: Ideally given with the birth of the anterior shoulder or immediately after the birth of the baby.
     • Carbetocin (Alternative/Specific Indications):
       • Dose: 100 mcg IV over 1 minute.
       • Indications: Recommended by WHO as an alternative to oxytocin, particularly in settings where oxytocin might lose efficacy due to heat exposure (it's heat-stable) or for specific risk groups. More expensive than oxytocin.
     • Ergometrine/Methylergometrine (Alternative, C/I with hypertension):
       • Dose: 0.2 mg IM or IV (IV dose may be higher).
       • Contraindications: Hypertension, pre-eclampsia, eclampsia, cardiac disease.
     • Misoprostol (Alternative in specific settings):
       • Dose: 600 mcg orally, sublingually, or rectally.
       • Indications: Useful in settings where injectable uterotonics (oxytocin, carbetocin) are not available or are contraindicated. Less effective than oxytocin and has more side effects (shivering, fever).
  2. Controlled Cord Traction (CCT):
     • Technique: After administering the uterotonic and only once signs of placental separation are observed, gently apply traction to the umbilical cord while simultaneously applying firm counter-pressure above the symphysis pubis with the other hand (Brandt-Andrews maneuver) to prevent uterine inversion.
     • Controversy: While traditionally part of AMTSL, routine CCT is not universally recommended by all guidelines, especially the latest WHO recommendations, which emphasize that CCT should only be performed by skilled birth attendants and only once signs of placental separation are clear.
  3. Uterine Massage:
     • Timing: After delivery of the placenta, routinely palpate the uterus to assess its tone and contraction. If the uterus is boggy, massage the fundus until it is firm.
     • Controversy: Routine sustained uterine massage after placental delivery is not recommended by WHO as part of AMTSL for the prevention of PPH in all women, as evidence does not support its additional benefit over uterotonics once the uterus is already firm. However, immediate assessment and massage if the uterus is atonic is critical.
• Stabilization: Ensure the placenta is delivered intact. Inspect the placenta for completeness. Inspect the birth canal for lacerations. Continue to monitor uterine tone and vaginal bleeding every 15 minutes for at least 2 hours postpartum.
• Emergency: If PPH occurs despite AMTSL, immediate additional interventions are required (e.g., bimanual uterine compression, additional uterotonics, fluid resuscitation, surgical intervention). This transitions from PPH prevention to PPH management.

Chronic Management

• AMTSL is an acute, peripartum intervention. There is no "chronic management" related to the procedure itself. Long-term follow-up would pertain to the mother's recovery from childbirth and any complications that may have arisen (e.g., anemia from PPH).

Treatment Algorithms

• First-Line (Standard AMTSL):
  1. Administer a prophylactic uterotonic (preferably Oxytocin 10 IU IM/IV).
  2. Assess for signs of placental separation.
  3. Once separation signs are present, perform Controlled Cord Traction with counter-pressure if skilled and confident.
  4. Deliver the placenta and membranes.
  5. Immediately after placental delivery, palpate the uterus to ensure it is firm and well-contracted. If not, perform uterine massage until it is firm.
  6. Inspect the placenta and membranes for completeness.
  7. Inspect the perineum, vagina, and cervix for lacerations and repair as needed.
  8. Monitor the mother closely for at least 2 hours postpartum (uterine tone, bleeding, vital signs).
• Second-Line/Refractory Cases (If PPH occurs despite AMTSL): This becomes a PPH management algorithm, which typically involves:
  1. Call for help/activate PPH protocol.
  2. Assess the "4 T's" (Tone, Tissue, Trauma, Thrombin).
  3. Begin aggressive uterine massage.
  4. Administer additional uterotonics (e.g., IV Oxytocin infusion, misoprostol, carboprost, methylergometrine if no contraindications).
  5. Fluid resuscitation (IV crystalloids, blood products).
  6. Consider bimanual uterine compression.
  7. Consider uterine balloon tamponade.
  8. Surgical intervention (e.g., uterine artery ligation, B-Lynch suture, hysterectomy) if other measures fail.

Complications

• Common:
  • Failure of AMTSL: Leading to PPH (most common).
  • Side effects of uterotonics:
    • Oxytocin: Nausea, vomiting, abdominal pain, rarely water intoxication with excessive IV doses. Rapid IV bolus can cause hypotension and tachycardia.
    • Ergometrine: Nausea, vomiting, hypertension, headache, abdominal pain.
    • Misoprostol: Shivering, fever, nausea, diarrhea.
• Serious:
  • Uterine inversion: Rare but severe complication, potentially caused by improper CCT (pulling on the cord before placental separation or without adequate counter-pressure).
  • Retained placental fragments: May occur if CCT is performed too forcefully or if the placenta does not fully separate.
  • Severe PPH: Leading to hypovolemic shock, disseminated intravascular coagulation (DIC), organ failure, acute respiratory distress syndrome (ARDS), or maternal death.

Prognosis

• Factors: The prognosis for women undergoing AMTSL is excellent, with a significantly reduced risk of PPH. Factors influencing outcomes if PPH occurs include the timely recognition of bleeding, prompt and effective management, availability of resources (blood products, skilled personnel), and underlying maternal health.
• Survival: AMTSL has been instrumental in reducing maternal mortality rates attributable to PPH globally.
• Quality of Life: Preventing PPH significantly improves maternal quality of life by reducing the risk of severe anemia, need for blood transfusions, prolonged hospital stays, and the psychological impact of a life-threatening obstetric emergency.

Prevention

• Primary: AMTSL is the primary prevention for PPH due to uterine atony. Universal application of AMTSL (specifically the prophylactic uterotonic) for all vaginal births is a cornerstone of safe delivery practices.
• Secondary: Early recognition and prompt management of PPH if it occurs despite AMTSL (e.g., the "4 T's" approach, PPH protocols).
• Tertiary: Management of complications arising from severe PPH (e.g., managing shock, DIC, providing intensive care support, addressing long-term sequelae like Sheehan's syndrome).

Special Populations

• Multiple Gestation: Higher risk of PPH due to uterine overdistension. AMTSL is crucial. Some clinicians consider slightly higher doses or a continuous infusion of oxytocin postpartum (e.g., 20-40 IU in 1000 mL IV fluid) after initial bolus.
• History of PPH: Women with a history of PPH are at increased risk of recurrence. Meticulous AMTSL is essential, and often a higher index of suspicion for developing PPH is maintained. Consider additional uterotonic options as part of a PPH protocol if the primary agent is insufficient.
• Anemia: Pre-existing anemia exacerbates the effects of blood loss. Aggressive PPH prevention and management are critical.
• Low-Resource Settings: Where access to injectable oxytocin may be limited or cold chain maintenance is challenging, heat-stable carbetocin or oral/sublingual misoprostol become more relevant options for PPH prevention. Training in proper CCT is also vital.

Clinical Pearls

• Diagnostic:
  • Always be vigilant for signs of placental separation before applying CCT. Pulling on an unseparated placenta can cause uterine inversion.
  • A firm, well-contracted uterus after placental delivery is the best indicator of successful uterine atony prevention.
• Treatment:
  • Oxytocin is king: 10 IU IM or slow IV push (over 1 minute) is the gold standard prophylactic uterotonic.
  • Timing is critical: Administer the uterotonic immediately after the birth of the baby.
  • Counter-pressure during CCT: Emphasize the importance of suprapubic counter-pressure during CCT to prevent uterine inversion.
  • Don't forget the full assessment: Even with successful AMTSL, always inspect the placenta for completeness and the birth canal for lacerations.
• Pitfalls:
  • Delay in uterotonic administration: Every minute counts in preventing PPH.
  • Improper CCT: Pulling without counter-pressure or before separation signs.
  • Ignoring a boggy uterus: Assuming a uterotonic alone is sufficient without manual assessment and massage if needed.
  • Over-reliance on routine uterine massage: While palpation is vital, sustained routine massage post-placental delivery for prevention is not evidence-based for all women and can be tiring for the care provider without added benefit if the uterus is already firm.

Recent Updates

• Guidelines (WHO 2018/2021): The WHO now strongly recommends a prophylactic uterotonic (preferably oxytocin) for all women undergoing vaginal birth to prevent PPH. Routine use of Controlled Cord Traction and uterine massage are no longer recommended as essential components for prevention in all women but can be performed by skilled providers. Early cord clamping is no longer recommended.
• Evidence:
  • Carbetocin: A heat-stable analogue of oxytocin, carbetocin 100 mcg IV has been shown to be as effective as oxytocin in preventing PPH, with potential advantages in settings without cold chain. The WHO recommends it as an alternative to oxytocin where available and affordable.
  • Routine Uterine Massage: Recent large trials and systematic reviews (e.g., Cochrane) have not shown additional benefit of routine sustained uterine massage after placental delivery in reducing PPH rates when a uterotonic has already been given. However, therapeutic massage for uterine atony remains essential.
• Controversies: The ongoing debate centers on the exact components of AMTSL beyond the prophylactic uterotonic. While the uterotonic is unequivocally essential, the routine application of CCT and uterine massage for all low-risk women continues to be discussed, with some guidelines still advocating for all three while others align more closely with the latest WHO recommendations.

Key References

• Guidelines:
  • World Health Organization (WHO) Guidelines for the Prevention and Treatment of Postpartum Hemorrhage (2018).
  • American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 183: Postpartum Hemorrhage (2017, reaffirmation 2022).
  • Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 52: Prevention and Management of Postpartum Haemorrhage (2016, update ongoing).
• Studies:
  • EPIICAL trial (Carbetocin): Widely cited study on the efficacy and safety of heat-stable carbetocin compared to oxytocin for the prevention of PPH.
  • Cochrane Reviews: Multiple systematic reviews on uterotonics for preventing PPH, and components of active management for PPH prevention.